舌和口腔鳞状细胞癌作为继发性恶性肿瘤：涉及哪些因素？
Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?
机构信息
New York University Cancer Institute, New York, New York 10016, USA, USA.
出版信息
Oncologist. 2013;18(3):245-7. doi: 10.1634/theoncologist.2013-0021. Epub 2013 Mar 13.
Abstract
The pegylated liposomal doxorubicin (PLD) was introduced clinically in the 1990s and won FDA approvals for the treatment of Kaposi's sarcoma (1995) and ovarian cancer (2000). At present, it seems prudent to engage patients in a discussion of risks (of a secondary cancer) versus benefits.
摘要
聚乙二醇脂质体阿霉素（PLD）于 20 世纪 90 年代在临床上推出，并获得 FDA 批准用于治疗卡波西肉瘤（1995 年）和卵巢癌（2000 年）。目前，似乎有必要与患者讨论风险（二次癌症的风险）与获益。
相似文献
1
Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?
Oncologist. 2013;18(3):245-7. doi: 10.1634/theoncologist.2013-0021. Epub 2013 Mar 13.
2
Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?
Oncologist. 2014 Apr;19(4):429. doi: 10.1634/theoncologist.2013-0421. Epub 2014 Mar 25.
3
Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs. secondary primary tumor.
Oral Oncol. 2015 Aug;51(8):738-44. doi: 10.1016/j.oraloncology.2015.04.016. Epub 2015 May 16.
4
A role for panendoscopy? Second primary tumour in early stage squamous cell carcinoma of the oral tongue.
J Laryngol Otol. 2015 Jan;129 Suppl 1:S27-31. doi: 10.1017/S0022215114002989.
5
Of course, early recognition of relapses in squamous cell carcinoma of the tongue is mandatory!
J Oral Maxillofac Surg. 2012 Dec;70(12):2731; author reply 2731. doi: 10.1016/j.joms.2012.07.053.
6
Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma.
Cancer Res. 1995 Jun 15;55(12):2656-9.
7
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
JAMA Oncol. 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34.
8
Heat shock protein and p53 expression in head and neck squamous cell carcinoma.
Otolaryngol Head Neck Surg. 1998 May;118(5):610-5. doi: 10.1177/019459989811800508.
9
Evolution of neck disease in patients with primary squamous cell carcinoma of the oral tongue, floor of mouth, and palatine arch, and clinically positive neck nodes neither fixed nor bilateral.
Cancer. 1972 Jan;29(1):23-30. doi: 10.1002/1097-0142(197201)29:1<23::aid-cncr2820290104>3.0.co;2-y.
10
TERT promoter mutation in patients with second primary of tongue squamous cell carcinoma.
Oral Oncol. 2021 Mar;114:105089. doi: 10.1016/j.oraloncology.2020.105089. Epub 2020 Nov 12.
引用本文的文献
1
Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Arch Gynecol Obstet. 2019 Jun;299(6):1641-1649. doi: 10.1007/s00404-019-05104-0. Epub 2019 Mar 1.
2
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.
Medicine (Baltimore). 2018 Feb;97(7):e9932. doi: 10.1097/MD.0000000000009932.
3
Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?
Oncologist. 2014 Apr;19(4):429. doi: 10.1634/theoncologist.2013-0421. Epub 2014 Mar 25.
本文引用的文献
1
Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer.
Oncologist. 2012;17(12):1598-9. doi: 10.1634/theoncologist.2012-0358.
2
Aggressive squamous cell carcinoma of the oral tongue in a woman with metastatic giant cell tumor treated with pegylated liposomal doxorubicin.
Oncologist. 2012;17(12):1596-7. doi: 10.1634/theoncologist.2012-0429.
3
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Ann Oncol. 2012 Dec;23(12):3104-3110. doi: 10.1093/annonc/mds172. Epub 2012 Jul 31.
4
Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin.
Oncologist. 2012;17(12):1594-5. doi: 10.1634/theoncologist.2011-0280. Epub 2012 May 23.
5
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?
Oncologist. 2012;17(12):1541-6. doi: 10.1634/theoncologist.2011-0216. Epub 2012 May 23.
6
Does long-term treatment with Doxil® predispose patients to oral cancer?
Int J Clin Oncol. 2013 Jun;18(3):554-5. doi: 10.1007/s10147-012-0400-1. Epub 2012 Mar 20.
7
The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
Int J Oncol. 2012 Mar;40(3):673-8. doi: 10.3892/ijo.2011.1249. Epub 2011 Nov 4.
8
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Mol Cancer Ther. 2011 Oct;10(10):2000-7. doi: 10.1158/1535-7163.MCT-11-0272. Epub 2011 Aug 11.
9
Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer.
J Natl Cancer Inst. 2011 Jan 19;103(2):160-1. doi: 10.1093/jnci/djq484. Epub 2010 Nov 29.
10
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Blood. 2010 Jan 14;115(2):326-30. doi: 10.1182/blood-2009-07-235051. Epub 2009 Nov 2.
Zotero 插件